News | Blood Testing | September 04, 2018

AI-Driven Blood Test Accurately Diagnoses Peripheral Artery Disease in Diabetic Patients

Prevencio’s multi-protein, AI-driven HART PAD biomarker test has potential to improve clinical outcomes and reduce costs in the treatment of diabetic patients

AI-Driven Blood Test Accurately Diagnoses Peripheral Artery Disease in Diabetic Patient

September 4, 2018 — Prevencio Inc. announced new data demonstrating its HART PAD test accurately diagnoses peripheral artery disease (PAD) in diabetes mellitus (DM) patients, a patient population in which PAD prevalence has traditionally been difficult to assess. Researchers believe these findings, presented at the 2018 European Society of Cardiology (ESC) Congress, Aug. 25-28 in Munich, Germany, could lead to early identification of PAD and improve patient clinical outcomes, as well as prevent patients without PAD from undergoing unnecessary, expensive and invasive tests.

The study is follow-on to data presented at the American Diabetes Association (ADA) 2018 Scientific Sessions in June demonstrating Prevencio’s HART CAD and HART CVE tests accurately diagnose coronary artery disease (CAD) and predict the risk for major adverse cardiac events (MACE) in DM patients. Similar to CAD, PAD is commonly due to atherosclerosis, a plaque buildup in the arteries which restricts blood flow.

In this study, researchers assessed the company’s artificial intelligence (AI)-driven HART PAD diagnostic test on patients enrolled in Massachusetts General Hospital’s (MGH) Catheter Sampled Blood Archive in Cardiovascular Disease (CASABLANCA) study. The HART PAD test algorithmically assesses six biomarkers linked to atherosclerosis, as well as a patient’s history of hypertension. In patients with DM, the HART PAD panel had excellent performance for diagnosis of PAD. Using a five-point score, a score of 1 had a 100 percent negative predictive value (NPV) and a score of 5 had a 95 percent positive predictive value (PPV). Additionally, the HART PAD panel was highly accurate in predicting the need for revascularization in patients with PAD. These results were comparable to those patients without DM.

Principal investigator James L. Januzzi, M.D., practicing cardiologist at MGH and professor of medicine at Harvard Medical School, said, “The HART PAD test may allow for the diagnosis and treatment of many more patients with currently undetected PAD. In the clinical setting, these findings could assist physicians to identify peripheral artery disease earlier, provide guideline-recommended care and monitor at-risk patients for vascular complications. We believe HART tests could also play an important role in identifying high-risk patients for enrollment in clinical trials, thereby saving time and lowering overall trial costs.”

PAD affects more than 202 million people worldwide and is often underdiagnosed and undertreated until the disease has reached advanced stages. Patients with DM are at substantial risk of developing PAD. Patients with PAD have increased risk of CAD, heart attack or stroke and, if left untreated, PAD can lead to foot or leg amputation.

For more information: www.prevenciomed.com

Related Content

FDA Proposes New Review Framework for AI-based Medical Devices
News | Artificial Intelligence | April 02, 2019 | Jeff Zagoudis, Associate Editor
U.S. Food and Drug Administration (FDA) Commissioner Scott Gottlieb, M.D., announced Tuesday the agency is pursuing a...
New Consensus Document Explores Ethical Use of AI in Radiology
News | Artificial Intelligence | March 05, 2019 | Jeff Zagoudis, Associate Editor
The American College of Radiology (ACR) is one of seven professional societies behind a new consensus document on the...
RSNA Offers First U.S. Spotlight Course on Artificial Intelligence
News | Artificial Intelligence | March 05, 2019
The Radiological Society of North America (RSNA) announced an expansion of its artificial intelligence (AI) education...
ACC Future Hub

Presenter delivers pitch at last year’s ACC Future Hub. This year during ACC.19, entrepreneurs will pitch software and hardware specific to cardiology in two categories– artificial intelligence and digitally enabled medical devices. (Image courtesy of ACC)

Feature | Artificial Intelligence | March 01, 2019 | By Greg Freiherr
Entrepreneurs to pitch innovative ideas at ACC
Siemens Healthineers Demonstrates Artificial Intelligence, Healthcare Digitalization at HIMSS19
News | Artificial Intelligence | February 13, 2019
At the 2019 Healthcare Information and Management Systems Society (HIMSS) global conference and exhibition, Feb. 11-15...
Medical Imaging AI Fundings Tops $1.2 Billion Worldwide
News | Artificial Intelligence | February 04, 2019
In 2018, capital investment in companies developing artificial intelligence (AI)-enabled medical image analysis...
Siemens Healthineers Debuts AI-Rad Companion Chest CT
News | Artificial Intelligence | January 25, 2019
January 25, 2019 — Siemens Healthineers presented its first intelligent software assistant for radiology, the AI-Rad
Artificial Intelligence in medical imaging was the top trend and buzz at RSNA 2018.

Artificial intelligence in medical imaging was the major buzz at RSNA 2018. The expo floor had a dedicated area just to highlight artificial intelligence software for medical imaging. More than 150 vendors on the expo floor were showing software using some level of AI or deep learning. 

Feature | Artificial Intelligence | January 17, 2019 | Dave Fornell, Editor
Artificial intelligence (AI) was by far the hottest trend discussed in sessions and across the expo floor at the worl
Overlay Init